Physician profile
Gary D Koenig
NPI 1861485724
$18,956.50
in general payments reported to CMS, 2019-2025
36 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $1,924 · 2021: $2,830 · 2022: $3,204 · 2023: $3,488 · 2024: $3,396 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,223 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,223.03 |
| Education | $273.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,475.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,782.11 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,897.61 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,532.55 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $1,126.35 | 2019-2025 | |
| Gilead Sciences, INC. | $723.00 | 2019-2025 | Livdelzi |
| Celgene Corporation | $552.77 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $517.66 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $509.99 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $434.61 | 2019-2023 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $427.47 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $423.15 | 2022-2025 | Dupixent |
| Amgen INC. | $390.62 | 2020-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $238.49 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $229.24 | 2019-2024 | Dificid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $228.08 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $208.70 | 2019-2023 | Rebyota |
| Ardelyx, INC. | $179.45 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $179.09 | 2024-2025 | Vowst |
| Celltrion USA INC. | $162.73 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $141.29 | 2023-2024 | |
| Echosens North America, INC. | $106.25 | 2024-2025 | Fibroscan, Fibroscan |
| Redhill Biopharma INC. | $77.51 | 2021-2022 | |
| Shionogi INC | $69.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.50 | 2022 | |
| Alfasigma USA, INC. | $46.04 | 2020 | |
| Phathom Pharmaceuticals, INC. | $36.10 | 2024 | Voquezna |
| Shire North American Group INC | $35.27 | 2019 | |
| Capsovision, INC. | $30.14 | 2024 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $29.18 | 2023 | |
| Organon LLC | $28.06 | 2023 | Renflexis, Hadlima |
| Resmed Corp | $22.23 | 2023 | |
| Exact Sciences Corporation | $21.83 | 2024 | |
| Boston Scientific Corporation | $20.51 | 2020 | |
| Dova Pharmaceuticals | $13.86 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.